**MINUTES**

**CPIC CONFERENCE CALL**

DATE: September 3, 2020

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Housekeeping announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a doodle link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Kelly will send the poll link. |
| Guidelines in progress | *CYP2D6*/opioid guideline update – almost complete  *CYP2C19*/clopidogrel update – in evidence review  *SLCO1B1*/simvastatin update – in evidence review, looking at 4 additional genes  *G6PD*/rasburicase update – in evidence review, including other drugs  *MTRNR1*/aminoglycosides – drafted recommendation, will start writing manuscript soon  SSRI-authorship plan underway |  |
| Update on CPIC informatics and CPIC database/API | Currently in the beta phase of testing with the CPIC Informatics members. This month, hoping to open it to the entire CPIC community. Slides will be included with the minutes. |  |
| 2021 CPIC in-person/virtual CPIC meeting | Feedback from 2019 conference – want more opportunities for networking. Topics of interest for programming includes laboratory reports, standardization of laboratory reports, impact of FDA regulations, direct-to-consumer testing. Planning both in-person and virtual versions of the meeting. Meeting tentatively planned for June 3 and 4, 2021. | Kelly will keep everyone updated on meeting planning and the finalized meeting dates. |
| Pharmacogenetics of beta-blockers: CPIC proposal for *ADRB1*, *GRK5*, and *CYP2D6* | Cameron Thomas, PharmD, postdoctoral fellow in genomic medicine at the University of Florida with Dr. Julie Johnson, presented a proposal for a CPIC guideline focused on beta-blockers with the genes *ADRB1*, *GRK5*, and *CYP2D6*. Opportunities and challenges were discussed. Slides will be included with the minutes. Link to recent review paper: [https://pubmed.ncbi.nlm.nih.gov/32726152/](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F32726152%2F&data=01%7C01%7CKelly.Caudle%40STJUDE.ORG%7Cdf0f3e95d7e64bf769a908d8502ba796%7C22340fa892264871b677d3b3e377af72%7C0&sdata=KRac%2BBdvbk7LnrQ2zw2bazlIhGmLUGzklNIfFR7ZQls%3D&reserved=0). | Individuals interested in pursuing possible development of such a guideline should contact Kelly ([kelly.caudle@stjude.org](mailto:kelly.caudle@stjude.org)) |